Early donor-specific HLA antibodies detected by screening in the first month posttransplant and kidney graft outcomes.

Donor-specific HLA antibodies (DSA) are related to antibody-mediated rejection (ABMR) and graft failure. The rationale and frequency of screening for anti-HLA antibodies in stable patients are not established. The aim of our study is to evaluate the impact of early DSA appearance in the first month...

Descripción completa

Detalles Bibliográficos
Autores: López del Moral, Covadonga, San Segundo Arribas, David, Ortega, María José, Martínez-Belotto, Miguel, Valero San Cecilio, Rosalía María, Belmar Vega, Lara, Valentín Muñoz, María de la Oliva, Rodrigo, Emilio, López Hoyos, Marcos, Ruiz San Millán, Juan Carlos|||0000-0002-7904-8730
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/38626
Acceso en línea:https://hdl.handle.net/10902/38626
Access Level:acceso abierto
Palabra clave:Kidney transplant
Antibody-mediated rejection
Donor-specific antibodies
Graft outcomes
HLA screening
Descripción
Sumario:Donor-specific HLA antibodies (DSA) are related to antibody-mediated rejection (ABMR) and graft failure. The rationale and frequency of screening for anti-HLA antibodies in stable patients are not established. The aim of our study is to evaluate the impact of early DSA appearance in the first month post-transplant on graft outcomes. All kidney transplant recipients between 1/1/2012?12/31/2022 with anti-HLA antibody screening by Luminex during the first month post-transplant were included. Patients with preformed or historical DSA and those with DSA detection after graft loss were excluded. The mean fluorescence intensity cut-off was 1,500. Three hundred fifty-three patients were included and the median time from transplant to first antibody sample was 30.0 days. During 3.8 years of follow-up, graft loss occurred in 9.1% and 19.5% had ABMR. A total of 8.5% developed early-DSA in the first month. Patients with early-DSA detection had more HLA sensitization at the time of transplant (p < 0.001). Multivariable analysis showed that the presence of early-DSA was an independent risk factor for ABMR. In conclusion, sensitized patients at the time of transplant have a higher risk of DSA formation in the first month, probably reflecting alloimmune memory, therefore early HLA antibody screening should be performed in this high-risk population.